Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury

Current Transplantation Reports

Volumn 2, Issue 3, 2015, Pages 222-232

  Valenzuela, Nicole M ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody mediated rejection; Endothelial cells; HLA antibodies; Leukocyte recruitment; Mammalian target of rapamycin (mTOR); Signal transduction

Indexed keywords

EID: 84961646967     PISSN: None     EISSN: 21963029     Source Type: Journal    
DOI: 10.1007/s40472-015-0065-6     Document Type: Article

References (119)

1. Frank R et al. Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies. Cardiovasc Pathol. doi:10.1016/j.carpath.2014.11.001
2. Torres IB et al. Comparing transplant glomerulopathy in the absence of C4d deposition and donor-specific antibodies to chronic antibody-mediated rejection. Clin Transpl. 2014;28:1148–54. doi:10.1111/ctr.12433. DOI: 10.1111/ctr.12433
3. DeNicola MM et al. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant Off Pub Int Soc Heart Trans. 2013;32:326–32. doi:10.1016/j.healun.2012.11.018. DOI: 10.1016/j.healun.2012.11.018
4. Valenzuela NM et al. HLA class I antibodies trigger increased adherence of monocytes to endothelial cells by eliciting an increase in endothelial P-selectin, and depending on subclass, by engaging FcgammaRs. J Immunol. 2013;190:6635–50. doi:10.4049/jimmunol.1201434. DOI: 10.4049/jimmunol.1201434
5. Valenzuela NM et al. Monocyte recruitment by HLA IgG-activated endothelium: the relationship between IgG subclass and FcγRIIa polymorphisms. Am J Trans. 2015. doi:10.1111/ajt.13174.
6. Jane-wit D et al. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-κB signaling in endothelial cells. Circulation. 2013;128:2504–16. doi:10.1161/circulationaha.113.002972. The investigators treated IFNγ-activated endothelial cells with polyclonal alloserum containing HLA (class I and class II) antibodies in the absence or presence of complement, and assessed endothelial late phase activation, including transcriptional upregulation of adhesion molecules and chemokines. They found that HLA antibodies triggered increased adhesion and activation of allogeneic CD4 T cells. DOI: 10.1161/CIRCULATIONAHA.113.002972
7. Taflin C et al. Study of the allogeneic response induced by endothelial cells expressing HLA class II after lentiviral transduction. In: van Endert P, editor. In antigen processing. New York: Humana Press; 2013. p. 461–72. doi:10.1007/978-1-62703-218-6_34.
8. Wang C et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J Clin Invest. 2013;123:1677–93. doi:10.1172/JCI66204. In this study, the authors evaluated the effect of chronic mTOR inhibition of endothelial cells on their alloimmunogenicity to T cells. Their results suggest that rapalogues modulate endothelial antigen presenting function. DOI: 10.1172/JCI66204
9. Jin YP et al. RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol. 2007;178:7911–22. DOI: 10.4049/jimmunol.178.12.7911
10. Lepin EJ et al. HLA class I signal transduction is dependent on Rho GTPase and ROK. Biochem Biophys Res Commun. 2004;323:213–7. doi:10.1016/j.bbrc.2004.08.082. DOI: 10.1016/j.bbrc.2004.08.082
11. Ziegler ME et al. HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol. 2012;303:C872–882. doi:10.1152/ajpcell.00199.2012. DOI: 10.1152/ajpcell.00199.2012
12. Ziegler ME et al. Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One. 2012;7:e29472. doi:10.1371/journal.pone.0029472. Ziegler et al. utilized a novel proteomic approach to describe the intracellular proteins that associate with the actin cytoskeleton after endothelial stimulation with HLA I antibodies. DOI: 10.1371/journal.pone.0029472
13. Coupel S et al. RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. Clin J Am Soc Nephrol JASN. 2004;15:2429–39. doi:10.1097/01.ASN.0000138237.42675.45. DOI: 10.1097/01.ASN.0000138237.42675.45
14. Jin YP et al. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol. 2002;168:5415–23. DOI: 10.4049/jimmunol.168.11.5415
15. Li F et al. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol. 2011;72:1150–9. doi:10.1016/j.humimm.2011.09.004. DOI: 10.1016/j.humimm.2011.09.004
16. Yoshizawa S et al. Focal adhesion kinase mediates human leukocyte histocompatibility antigen class II-induced signaling in gingival fibroblasts. J Periodontal Res. 2007;42:572–9. doi:10.1111/j.1600-0765.2007.00985.x. DOI: 10.1111/j.1600-0765.2007.00985.x
17. Murali A, Rajalingam K. Small Rho GTPases in the control of cell shape and mobility. Cell Mol Life Sci CMLS. 2014;71:1703–21. doi:10.1007/s00018-013-1519-6. DOI: 10.1007/s00018-013-1519-6
18. Wojciak-Stothard B et al. Rac and Rho play opposing roles in the regulation of hypoxia/reoxygenation-induced permeability changes in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2005;288:L749–760. doi:10.1152/ajplung.00361.2004. DOI: 10.1152/ajplung.00361.2004
19. Jindra PT et al. MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway. Biochem Biophys Res Commun. 2008;369:781–7. doi:10.1016/j.bbrc.2008.02.093. DOI: 10.1016/j.bbrc.2008.02.093
20. Geiger B et al. Environmental sensing through focal adhesions. Nat Rev Mol Cell Biol. 2009;10:21–33. doi:10.1038/nrm2593. DOI: 10.1038/nrm2593
21. Jaqaman K, Grinstein S. Regulation from within: the cytoskeleton in transmembrane signaling. Trends Cell Biol. 2012;22:515–26. doi:10.1016/j.tcb.2012.07.006. DOI: 10.1016/j.tcb.2012.07.006
22. Tojkander S et al. Actin stress fibers–assembly, dynamics and biological roles. J Cell Sci. 2012;125:1855–64. doi:10.1242/jcs.098087. DOI: 10.1242/jcs.098087
23. Hordijk PL. Endothelial signalling events during leukocyte transmigration. FEBS J. 2006;273:4408–15. doi:10.1111/j.1742-4658.2006.05440.x. DOI: 10.1111/j.1742-4658.2006.05440.x
24. Jin YP et al. Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus. Am J Transplant. 2014;14:806–19. doi:10.1111/ajt.12669. In this work, Jin et al. report that HLA I antibody-stimulated endothelial proliferation can be abrogated by rapalogues sirolimus and everolimus. Moreover, everolimus was more potent at inhibiting mTORC2 and its target ERK, and therefore was more effective at preventing endothelial migration and proliferation compared with sirolimus, which was less efficient at inhibiting mTORC2. DOI: 10.1111/ajt.12669
25. Iwasaki K et al. Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction: implication of accommodation. Transplantation. 2012;93:390–7. doi:10.1097/TP.0b013e3182424df3. DOI: 10.1097/TP.0b013e3182424df3
26. Narayanan K et al. HLA class I antibody mediated accommodation of endothelial cells via the activation of PI3K/cAMP dependent PKA pathway. Transpl Immunol. 2006;15:187–97. doi:10.1016/j.trim.2005.09.005. DOI: 10.1016/j.trim.2005.09.005
27. Jin YP et al. Anti-HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xL expression in endothelial cells. Hum Immunol. 2004;65:291–302. doi:10.1016/j.humimm.2004.01.002. DOI: 10.1016/j.humimm.2004.01.002
28. Le Bas-Bernardet S et al. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation. 2004;78:1729–39. DOI: 10.1097/01.TP.0000147339.31581.99
29. Hidalgo LG et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10:1812–22. doi:10.1111/j.1600-6143.2010.03201.x. DOI: 10.1111/j.1600-6143.2010.03201.x
30. Sis B et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant. 2009;9:2312–23. doi:10.1111/j.1600-6143.2009.02761.x. DOI: 10.1111/j.1600-6143.2009.02761.x
31. Loupy A et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant. 2009;9:2561–70. doi:10.1111/j.1600-6143.2009.02813.x. DOI: 10.1111/j.1600-6143.2009.02813.x
32. Papadimitriou JC et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation. 2013;95:128–36. doi:10.1097/TP.0b013e3182777f28. DOI: 10.1097/TP.0b013e3182777f28
33. Wiebe C et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–67. doi:10.1111/j.1600-6143.2012.04013.x. Wiebe et al. propose a model of the “natural history of antibodies” in which subclinical or indolent graft injury occurs close to the time of first de novo donor specific antibodies appearance, while the histological and clinical manifestations of graft dysfunction occur later. DOI: 10.1111/j.1600-6143.2012.04013.x
34. Everly MJ et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410–7. doi:10.1097/TP.0b013e31827d62e3. DOI: 10.1097/TP.0b013e31827d62e3
35. Mehra MR et al. International society for heart and lung transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant Off Pub Int Soc Heart Trans. 2010;29:717–27. doi:10.1016/j.healun.2010.05.017. DOI: 10.1016/j.healun.2010.05.017
36. Haas M et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–83. doi:10.1111/ajt.12590. DOI: 10.1111/ajt.12590
37. Lobo LJ et al. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant Off Pub Int Soc Heart Trans. 2013;32:70–7. doi:10.1016/j.healun.2012.10.007. DOI: 10.1016/j.healun.2012.10.007
38. Stewart S et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant Off Pub Int Soc Heart Trans. 2007;26:1229–42. doi:10.1016/j.healun.2007.10.017. DOI: 10.1016/j.healun.2007.10.017
39. Atkinson C et al. Angiogenesis occurs within the intimal proliferation that characterizes transplant coronary artery vasculopathy. J Heart Lung Transplant Off Pub Int Soc Heart Trans. 2005;24:551–8. doi:10.1016/j.healun.2004.03.012. DOI: 10.1016/j.healun.2004.03.012
40. Libby P, Zhao DX. Allograft arteriosclerosis and immune-driven angiogenesis. Circulation. 2003;107:1237–9. DOI: 10.1161/01.CIR.0000059744.64373.08
41. Tanaka H et al. Endothelial and smooth muscle cells express leukocyte adhesion molecules heterogeneously during acute rejection of rabbit cardiac allografts. Am J Pathol. 1994;144:938–51.
42. Zhao XM et al. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation. 2001;103:525–31. DOI: 10.1161/01.CIR.103.4.525
43. Jindra PT et al. Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol. 2008;180:2214–24. DOI: 10.4049/jimmunol.180.4.2214
44. Jindra PT et al. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol. 2008;180:2357–66. DOI: 10.4049/jimmunol.180.4.2357
45. Hirohashi T et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant. 2010;10:510–7. doi:10.1111/j.1600-6143.2009.02958.x. DOI: 10.1111/j.1600-6143.2009.02958.x
46. Russell PS et al. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol. 1994;152:5135–41.
47. Lepin EJ et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant. 2006;6:1560–71. doi:10.1111/j.1600-6143.2006.01355.x. DOI: 10.1111/j.1600-6143.2006.01355.x
48. Li F et al. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts. J Heart Lung Transplant. 2014. doi:10.1016/j.healun.2014.09.047.
49. Tible M et al. Pathologic classification of antibody-mediated rejection correlates with donor-specific antibodies and endothelial cell activation. J Heart Lung Transplant. 2013;32:769–76. doi:10.1016/j.healun.2013.05.012. The parallel findings reported by Li et al. and Tible et al. demonstrate that detection of activated signaling proteins implicated in HLA I antibody induced intracellular signaling (including phosphorylated S6K and S6RP) facilitates diagnosis of antibody-mediated rejection in cardiac allografts. DOI: 10.1016/j.healun.2013.05.012
50. Bruneau S et al. DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses. Blood. 2013;122:1833–42. doi:10.1182/blood-2013-03-488486. This study describes a novel negative regulator of mTOR, DEPTOR, in endothelial cells and its impact on endothelial immunogenicity. Knockdown of DEPTOR resulted in constitutive activation of mTOR, and increased angiogenic functions, chemokine expression and adhesion of T cells, demonstrating that mTOR is a central regulator of these functions. The authors propose that DEPTOR is a putative therapeutic target to modulate mTOR activity. DOI: 10.1182/blood-2013-03-488486
51. Arora S et al. Effect of everolimus introduction on cardiac allograft vasculopathy–results of a randomized, multicenter trial. Transplantation. 2011;92:235–43. doi:10.1097/TP.0b013e31822057f1. DOI: 10.1097/TP.0b013e31822057f1
52. Kobashigawa JA et al. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. JACC Heart Failure. 2013;1:389–99. doi:10.1016/j.jchf.2013.07.002. DOI: 10.1016/j.jchf.2013.07.002
53. Daly KP et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant Off Pub Int Society Heart Trans. 2013;32:120–8. doi:10.1016/j.healun.2012.09.030. DOI: 10.1016/j.healun.2012.09.030
54. Reinders ME et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation. 2003;76:224–30. doi:10.1097/01.TP.0000071363.55007.D0. DOI: 10.1097/01.TP.0000071363.55007.D0
55. Lemstrom KB et al. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation. 2002;105:2524–30. DOI: 10.1161/01.CIR.0000016821.76177.D2
56. Bieri M et al. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol. 2009;41:2422–30. doi:10.1016/j.biocel.2009.06.009. DOI: 10.1016/j.biocel.2009.06.009
57. Galvani S et al. A key role for matrix metalloproteinases and neutral sphingomyelinase-2 in transplant vasculopathy triggered by anti-HLA antibody. Circulation. 2011;124:2725–34. doi:10.1161/CIRCULATIONAHA.111.021790. DOI: 10.1161/CIRCULATIONAHA.111.021790
58. Fishbein GA, Fishbein MC. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Hum Immunol. 2012;73:1213–7. doi:10.1016/j.humimm.2012.07.011. DOI: 10.1016/j.humimm.2012.07.011
59. Tinckam KJ et al. Glomerular monocytes predict worse outcomes after acute renal allograft rejection independent of C4d status. Kidney Int. 2005;68:1866–74. doi:10.1111/j.1523-1755.2005.00606.x. DOI: 10.1111/j.1523-1755.2005.00606.x
60. Xu L et al. Increased macrophage density of cardiac allograft biopsies is associated with antibody-mediated rejection and alloantibodies to HLA antigens. Clin Transpl. 2014;28:554–60. doi:10.1111/ctr.12348. DOI: 10.1111/ctr.12348
61. Hirohashi T et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012;12:313–21. doi:10.1111/j.1600-6143.2011.03836.x. DOI: 10.1111/j.1600-6143.2011.03836.x
62. Valenzuela NM et al. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant. 2013;13:299–311. doi:10.1111/ajt.12016. DOI: 10.1111/ajt.12016
63. Abe T et al. Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts. Am J Transplant. 2014;14:1753–64. doi:10.1111/ajt.12780. DOI: 10.1111/ajt.12780
64. Lowenstein CJ et al. Regulation of Weibel-Palade body exocytosis. Trends Cardiovasc Med. 2005;15:302–8. doi:10.1016/j.tcm.2005.09.005. DOI: 10.1016/j.tcm.2005.09.005
65. Yamakuchi M et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A. 2007;104:1301–6. doi:10.1073/pnas.0602035104. DOI: 10.1073/pnas.0602035104
66. Morrell CN et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res. 2008;102:777–85. doi:10.1161/CIRCRESAHA.107.170332. DOI: 10.1161/CIRCRESAHA.107.170332
67. Kuo HH et al. Platelets in early antibody-mediated rejection of renal transplants. Clin J Am Soc Nephrol JASN. 2014. doi:10.1681/ASN.2013121289.
68. da Costa Martins P et al. Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler Thromb Vasc Biol. 2004;24:193–9. doi:10.1161/01.ATV.0000106320.40933.E5. DOI: 10.1161/01.ATV.0000106320.40933.E5
69. Mannam VK et al. The fate of renal allografts hinges on responses of the microvascular endothelium. Exp Mol Pathol. 2013;94:398–411. doi:10.1016/j.yexmp.2012.06.002. DOI: 10.1016/j.yexmp.2012.06.002
70. Naemi FM et al. Anti-donor HLA class I antibodies: pathways to endothelial cell activation and cell-mediated allograft rejection. Transplantation. 2013;96:258–66. doi:10.1097/TP.0b013e3182985504. DOI: 10.1097/TP.0b013e3182985504
71. Meguro M et al. Ligation of IFN-gamma-induced HLA-DR molecules on fibroblasts induces RANTES expression via c-Jun N-terminal kinase (JNK) pathway. Cytokine. 2003;22:107–15. DOI: 10.1016/S1043-4666(03)00123-6
72. Wang C et al. Rapamycin antagonizes TNF induction of VCAM-1 on endothelial cells by inhibiting mTORC2. Isr J Exp Med. 2014;211:395–404. doi:10.1084/jem.20131125. DOI: 10.1084/jem.20131125
73. Samsonov D et al. Differential activation of human T cells to allogeneic endothelial cells, epithelial cells and fibroblasts in vitro. Transl Res. 2012;1:4. doi:10.1186/2047-1440-1-4. DOI: 10.1186/2047-1440-1-4
74. Shiao SL et al. Human effector memory CD4+ T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol. 2007;179:4397–404. DOI: 10.4049/jimmunol.179.7.4397
75. Ma W, Pober JS. Human endothelial cells effectively costimulate cytokine production by, but not differentiation of, naive CD4+ T cells. J Immunol. 1998;161:2158–67.
76. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell? Nat Rev Immunol. 2014;14:719–30. doi:10.1038/nri3754. DOI: 10.1038/nri3754
77. Pober JS, Tellides G. Participation of blood vessel cells in human adaptive immune responses. Trends Immunol. 2012;33:49–57. doi:10.1016/j.it.2011.09.006. DOI: 10.1016/j.it.2011.09.006
78. Taflin C et al. Human endothelial cells generate Th17 and regulatory T cells under inflammatory conditions. Proc Natl Acad Sci U S A. 2011;108:2891–6. doi:10.1073/pnas.1011811108. DOI: 10.1073/pnas.1011811108
79. Gaughan A et al. Key role for CD4 T cells during mixed antibody-mediated rejection of renal allografts. Am J Transplant. 2014;14:284–94. doi:10.1111/ajt.12596. DOI: 10.1111/ajt.12596
80. Sumen C et al. T cell receptor antagonism interferes with MHC clustering and integrin patterning during immunological synapse formation. J Cell Biol. 2004;166:579–90. doi:10.1083/jcb.200404059. DOI: 10.1083/jcb.200404059
81. Vogt AB et al. Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains. Immunol Rev. 2002;189:136–51. DOI: 10.1034/j.1600-065X.2002.18912.x
82. Miro F et al. T cell-dependent activation of dendritic cells requires IL-12 and IFN-gamma signaling in T cells. J Immunol. 2006;177:3625–34. DOI: 10.4049/jimmunol.177.6.3625
83. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7:817–23. doi:10.1038/nri2163. DOI: 10.1038/nri2163
84. Al-Alwan MM et al. Cutting edge: dendritic cell actin cytoskeletal polarization during immunological synapse formation is highly antigen-dependent. J Immunol. 2003;171:4479–83. DOI: 10.4049/jimmunol.171.9.4479
85. Delaguillaumie A et al. Contrasting cytoskeletal regulation of MHC class II peptide presentation by human B cells or dendritic cells. Eur J Immunol. 2008;38:1096–105. doi:10.1002/eji.200737455. DOI: 10.1002/eji.200737455
86. Drénou B et al. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. J Leukoc Biol. 2005;77:560–7. doi:10.1189/jlb.0704423. DOI: 10.1189/jlb.0704423
87. Bains SK et al. Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia. 2003;17:1357–65. doi:10.1038/sj.leu.2402976. DOI: 10.1038/sj.leu.2402976
88. Holling TM et al. Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. Hum Immunol. 2004;65:282–90. doi:10.1016/j.humimm.2004.01.005. DOI: 10.1016/j.humimm.2004.01.005
89. Matsuoka T et al. Monocytes are differentially activated through HLA-DR, -DQ, and -DP molecules via mitogen-activated protein kinases. J Immunol. 2001;166:2202–8. DOI: 10.4049/jimmunol.166.4.2202
90. Nabavi N et al. Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature. 1992;360:266–8. doi:10.1038/360266a0. DOI: 10.1038/360266a0
91. Setterblad N et al. Cognate MHC-TCR interaction leads to apoptosis of antigen-presenting cells. J Leukoc Biol. 2004;75:1036–44. doi:10.1189/jlb.0703356. DOI: 10.1189/jlb.0703356
92. Truman JP et al. HLA class II molecule signal transduction leads to either apoptosis or activation via two different pathways. Cell Immunol. 1996;172:149–57. doi:10.1006/cimm.1996.0227. DOI: 10.1006/cimm.1996.0227
93. Altomonte M et al. The overlooked “nonclassical” functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. J Cell Physiol. 1999;179:251–6. doi:10.1002/(SICI)1097-4652(199906)179:3%3C251::AID-JCP2%3E3.0.CO;2-P. DOI: 10.1002/(SICI)1097-4652(199906)179:3<251::AID-JCP2>3.0.CO;2-P
94. Faure-Andre G et al. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science. 2008;322:1705–10. doi:10.1126/science.1159894. DOI: 10.1126/science.1159894
95. Rubio G et al. Cross-linking of MHC class I molecules on human NK cells inhibits NK cell function, segregates MHC I from the NK cell synapse, and induces intracellular phosphotyrosines. J Leukoc Biol. 2004;76:116–24. doi:10.1189/jlb.1103597. DOI: 10.1189/jlb.1103597
96. Corral-San Miguel R et al. MHC-I molecules selectively inhibit cell-mediated cytotoxicity triggered by ITAM-coupled activating receptors and 2B4. PLoS ONE. 2014;9:e107054. doi:10.1371/journal.pone.0107054. In this work, NK cell cytotoxicity against tumor cells was significantly inhibited by concurrent crosslinking of MHC I, which induced negative crosstalk signaling pathways to antagonize activating receptors. DOI: 10.1371/journal.pone.0107054
97. El Fakhry Y et al. Delineation of the HLA-DR region and the residues involved in the association with the cytoskeleton. J Biol Chem. 2004;279:18472–80. doi:10.1074/jbc.M401159200. DOI: 10.1074/jbc.M401159200
98. Zhang X et al. HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration. Sci Signal. 2010;3:ra85–10.1126/scisignal.2001158.
99. Capps GG, Zuniga MC. Phosphorylation of class I MHC molecules in the absence of phorbol esters is an intracellular event and may be characteristic of trafficking molecules. Mol Immunol. 2000;37:59–71. DOI: 10.1016/S0161-5890(00)00019-5
100. Guild BC, Strominger JL. HLA-A2 antigen phosphorylation in vitro by cyclic AMP-dependent protein kinase. Sites of phosphorylation and segmentation in class I major histocompatibility complex gene structure. J Biol Chem. 1984;259:13504–10.
101. Xu S et al. Constitutive MHC class I molecules negatively regulate TLR-triggered inflammatory responses via the Fps-SHP-2 pathway. Nat Immunol. 2012;13:551–9. doi:10.1038/ni.2283. DOI: 10.1038/ni.2283
102. Anderson HA, Roche PA. Phosphorylation regulates the delivery of MHC class II invariant chain complexes to antigen processing compartments. J Immunol. 1998;160:4850–8.
103. Engering A, Pieters J. Association of distinct tetraspanins with MHC class II molecules at different subcellular locations in human immature dendritic cells. Int Immunol. 2001;13:127–34. DOI: 10.1093/intimm/13.2.127
104. Hoorn T et al. Dynamics within tetraspanin pairs affect MHC class II expression. J Cell Sci. 2012;125:328–39. doi:10.1242/jcs.088047. DOI: 10.1242/jcs.088047
105. Lagaudriere-Gesbert C et al. The tetraspanin protein CD82 associates with both free HLA class I heavy chain and heterodimeric beta 2-microglobulin complexes. J Immunol. 1997;158:2790–7.
106. Petersen SH et al. The role of tetraspanin CD63 in antigen presentation via MHC class II. Eur J Immunol. 2011;41:2556–61. doi:10.1002/eji.201141438. DOI: 10.1002/eji.201141438
107. Unternaehrer JJ et al. The tetraspanin CD9 mediates lateral association of MHC class II molecules on the dendritic cell surface. Proc Natl Acad Sci U S A. 2007;104:234–9. doi:10.1073/pnas.0609665104. DOI: 10.1073/pnas.0609665104
108. Mori Y et al. Inhibitory immunoglobulin-like receptors LILRB and PIR-B negatively regulate osteoclast development. J Immunol. 2008;181:4742–51. DOI: 10.4049/jimmunol.181.7.4742
109. Shiroishi M et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci U S A. 2006;103:16412–7. doi:10.1073/pnas.0605228103. DOI: 10.1073/pnas.0605228103
110. Willcox BE et al. Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol. 2003;4:913–9. doi:10.1038/ni961. DOI: 10.1038/ni961
111. Jones DC et al. HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol. 2011;186:2990–7. doi:10.4049/jimmunol.1003078. DOI: 10.4049/jimmunol.1003078
112. Held W, Mariuzza RA. Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nat Rev Immunol. 2008;8:269–78. doi:10.1038/nri2278. DOI: 10.1038/nri2278
113. Liu X et al. Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol. 2011;12:416–24. doi:10.1038/ni.2015. DOI: 10.1038/ni.2015
114. Lee H et al. Synapse elimination and learning rules co-regulated by MHC class I H2-Db. Nature. 2014;509:195–200. doi:10.1038/nature13154. New work in murine models shows that MHC I is required for neuronal patterning. Knockdown of classical MHC I prevents synapse elimination and neuronal pruning that is essential for development in the central nervous system, identifying a novel role for MHC I outside the classical functions in the immune system. DOI: 10.1038/nature13154
115. Ramalingam TS et al. Interaction of class I human leukocyte antigen (HLA-I) molecules with insulin receptors and its effect on the insulin-signaling cascade. Mol Biol Cell. 1997;8:2463–74. DOI: 10.1091/mbc.8.12.2463
116. Reiland J, Edidin M. Chemical cross-linking detects association of insulin receptors with four different class I human leukocyte antigen molecules on cell surfaces. Diabetes. 1993;42:619–25. DOI: 10.2337/diab.42.4.619
117. Dixon-Salazar TJ et al. MHC class I limits hippocampal synapse density by inhibiting neuronal insulin receptor signaling. J Neurosci Off J Soc Neurosci. 2014;34:11844–56. doi:10.1523/JNEUROSCI.4642-12.2014. DOI: 10.1523/JNEUROSCI.4642-12.2014
118. Giancotti FG. Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol Sci. 2007;28:506–11. doi:10.1016/j.tips.2007.08.004. DOI: 10.1016/j.tips.2007.08.004
119. Zhang X, Reed EF. HLA class I: an unexpected role in integrin beta4 signaling in endothelial cells. Hum Immunol. 2012;73:1239–44. doi:10.1016/j.humimm.2012.06.013. DOI: 10.1016/j.humimm.2012.06.013